Susan G. Komen ® Invests Nearly $11 Million to Accelerate Breakthroughs in Breast Cancer Research
'We are proud to support these exceptional researchers who are pushing the boundaries of what's possible in breast cancer science,' said Paula Schneider, President and CEO of Susan G. Komen. 'Research saves lives, and now more than ever, we must invest in science that brings hope to patients — especially those facing the most aggressive forms of breast cancer.'
Through this research investment, Komen is prioritizing the most pressing challenges facing patients, including metastatic breast cancer, health inequities and the need for more precise, personalized treatment strategies to improve care and outcomes for everyone impacted by breast cancer.
Key Highlights of Komen's 2025 Research Investment:
54% of funding targets metastatic breast cancer — the most advanced stage of the disease, responsible for the nearly 43,000 deaths each year in the U.S.
50% focused on precision medicine to tailor treatments to each patient's unique biology.
21% invested in addressing disparities to eliminate inequities in breast cancer care and outcomes.
25 researchers funded, including 10 early-career investigators, representing the next generation of scientific leaders.
'Komen's commitment to breast cancer research comes at a pivotal time and will drive meaningful advances in our understanding of the disease and care of patients,' said Ann Partridge, M.D., M.P.H., Chief Scientific Advisor for Komen. 'By fueling science that is both innovative and inclusive, we're accelerating progress where patients need it most — while building a foundation for individualized care for all.'
Komen is the largest nonprofit funder of breast cancer research outside the U.S. government, investing nearly $1.1 billion since its inception. Unlike many research institutions, Komen's work is powered entirely by the generosity of individual donors, corporate partners and community supporters.
'Investing in top scientific talent is one of the most powerful ways we can drive progress,' said Jennifer A. Pietenpol, Ph.D., Chief Scientific Advisor for Komen. 'Komen's commitment, especially to early-career researchers, cultivates a vibrant ecosystem where bold ideas and pioneering research can thrive, accelerating our path toward the cures we urgently seek.'
REACHing Deeper into Research Advocacy
Komen's commitment to research goes beyond funding — it includes empowering people to bring their lived experiences into the heart of science. Through its recently launched REACH (Research Education and Advocate Community Hub) initiative, Komen invites patients, survivors and co-survivors to become research advocates and help shape research. ShareforCures®, Komen's breast cancer registry, provides breast cancer patients and survivors with a new, secure and easy way to share health data to help accelerate breast cancer research.
As Komen deepens its investment in research, the need for collaboration — between scientists, clinicians, advocates and patients — has never been greater. Through strategic funding, innovative patient-centric scientific programs, robust advocacy programs, education and patient support services, Susan G. Komen is leading the way so patients can benefit from scientific breakthroughs and receive the care they need to live longer, healthier lives.
Recipients of Komen Grants
Recipients of Career Catalyst Research Grants
Chun-Kan Chen, PhD, MS, Washington University in St. Louis
Miriam Jacobs, MD, Georgetown University
Martina Molgora, PhD, MSc., H. Lee Moffitt Cancer Center & Research Institute, Inc.
Daniel O'Neil, MD, MPH, Yale University
Claire Sathe, MD, JD, Columbia University Irving Medical Center
Na Zhao, PhD, Baylor College of Medicine
Recipients of Career Transition Awards
Charles Dai, MD, Massachusetts General Hospital
Avantika Gupta, PhD, MSc, Memorial Sloan-Kettering Cancer Center
Alissa Michel, MD, Columbia University Irving Medical Center
Veena Padmanaban, PhD, MS, The Rockefeller University
Recipients of Leadership Grants
Alan Ashworth, PhD, University of California, San Francisco
Tuya Pal, MD, Vanderbilt University Medical Center
Rulla Tamimi, ScD, MS, Weill Medical College of Cornell University
Kornelia Polyak, MD, PhD, Dana-Farber Cancer Institute
Christina Curtis, PhD, MSc, Stanford University School of Medicine
Jeffrey Rosen, PhD, Baylor College of Medicine
Tracy Battaglia, MD, Yale University
Allison Kurian, MD, MSc, Stanford University School of Medicine
Nancy Lin, MD, Dana-Farber Cancer Institute
Ben Ho Park, MD, PhD, Vanderbilt University Medical Center
Jennifer Pietenpol, PhD, Vanderbilt University Medical Center
Recipients of Opportunity Grants
Filipa Lynce, MD, Dana Farber Cancer Institute
Michele Cote, PhD, MPH, Indiana University
Antonio Wolff, MD, Johns Hopkins University School of Medicine
Recipient of Scientific Strategy and Programs Grant
Adrian Lee, PhD, University of Pittsburgh
To learn more about Komen's research initiatives, visit komen.org/research. To explore how you can get involved with REACH (Research Education and Advocate Community Hub), visit komen.org/REACH
About Susan G. Komen ®
Susan G. Komen ® is the world's leading nonprofit breast cancer organization, working to save lives and end breast cancer forever. Komen has an unmatched, comprehensive 360-degree approach to fighting this disease across all fronts and supporting millions of people in the U.S. and in countries worldwide. We advocate for patients, drive research breakthroughs, improve access to high-quality care, offer direct patient support and empower people with trustworthy information. Founded by Nancy G. Brinker, who promised her sister, Susan G. Komen, that she would end the disease that claimed Suzy's life, Komen remains committed to supporting those affected by breast cancer today, while tirelessly searching for tomorrow's cures. Visit komen.org or call 1-877 GO KOMEN. Connect with us on social at www.komen.org/contact-us/follow-us/.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
Incredible discovery hidden beneath major Aussie tourist highway
Beneath the dusty stretch of highway frequented by tourists heading to the Top End, a hidden world has come to light. Deep underground, in pitch-black layers of porous limestone rock, hundreds of metres beneath the surface, scientists have found a thriving ecosystem filled with strange, blind creatures. Known as stygofauna, that may hold the key to protecting Australia's groundwater for generations to come. These tiny animals live in water-filled cracks and pockets within underground limestone aquifers (rock formations that store water). They've adapted to total darkness over millions of years, often losing their eyesight and developing unusual features to survive in cold, low-oxygen conditions. Though smaller than a grain of rice, stygofauna play a surprisingly big role. They help keep groundwater clean by feeding on bacteria and breaking down organic matter, acting like a natural filtration system deep below the surface. In simple terms, they're nature's underground clean-up crew, quietly recycling the water many Australians rely on, CSIRO Senior Research Scientist Dr Paul McInerney told Yahoo News. It's not the first discovery of stygofauna in general, but it does highlight the need for careful groundwater management in that region, McInerney explained. In a new report, he said that by researching these communities, we can better understand groundwater ecosystems, assess aquatic health and how human activity affects our water. The creatures were found in the Beetaloo Sub-basin in the Northern Territory — a region rich in gas reserves and the subject of ongoing development interest. Scientists sampled water from 33 bores, using fine mesh nets, environmental DNA (eDNA) testing, and specialist video cameras that can record footage up to 200 metres underground. "We used a specialist bore-hole video camera that shines a light in front of the lens and lowered it into the well using a cable. This allowed us to record footage up to 200m below the surface," McInerney said. "In some wells, there were no visible stygofauna. However, the eDNA analysis of water samples revealed the presence of stygofauna." The study found unique combinations of species in different locations, highlighting just how localised and potentially fragile these ecosystems are. Among the stygofauna found were tiny, translucent creatures, including one resembling a prawn. Populations of the shrimp-like species Parisia unguis found in the Beetaloo Sub-basin were genetically different from one another, meaning the groups living in different bores don't mix much and are likely isolated from each other. That matters because it shows just how fragile and localised these underground ecosystems are. If each population of Parisia unguis is isolated, then damage to even one bore or area could wipe out a unique genetic group that doesn't exist anywhere else. The Beetaloo Sub-basin in the Northern Territory is currently a major focus of gas exploration and development. While full-scale commercial production hasn't commenced yet, significant activities are underway by companies such as Empire Energy, Tamboran Resources and Santos. Recently, there have been ongoing protests against gas exploration and fracking in the Beetaloo Sub-basin. Traditional owners, including members of the Nurrdalinji Aboriginal Corporation, have voiced strong opposition, citing concerns over environmental impacts, threats to sacred sites, and inadequate consultation processes. Environmental groups and activists have also joined these protests, highlighting potential risks to groundwater and climate implications McInerney said the CSIRO's research did not directly investigate the impact of gas drilling or mining. However, he said any activity that disrupts aquifers could put these creatures, and the delicate ecosystems they support, at risk. "Any activities that change the physical or chemical condition of aquifers in the Beetaloo Sub-basin may threaten the persistence and distribution of stygofauna species," he said. In other words, disturbing the water table through drilling, pollution, or overuse could damage or even wipe out entire populations of creatures we barely understand. One of the most compelling reasons to care about these hidden ecosystems is how little we know about them — and how much we could lose before we ever get the chance to study them. Scientists say stygofauna could one day act as indicators of pollution or aquifer stress, but we're not there yet. Pumping too much groundwater threatens thousands of underground species Households to face decades of water restrictions due to worrying trend 'Poor management': regulator in hot water over licences The latest research has laid the groundwork for bigger questions, and possibly more focused conservation. "There is potential for new projects to expand the known distribution of NT stygofauna and to improve our understanding of their ecology," McInerney said. "Results of these and other CSIRO studies are important for informing appropriate policy and management responses to development proposals." Though invisible to most of us, stygofauna exist across Australia — not just in the NT — and are found anywhere aquifers offer the right balance of pore space, water flow and nutrient conditions. Understanding them helps us to support agriculture, industry, and even our drinking water. Love Australia's weird and wonderful environment? 🐊🦘😳 Get our new newsletter showcasing the week's best stories.
Health Line
4 hours ago
- Health Line
What We Know About CBD for Macular Degeneration (AMD)
CBD has similar pain-relieving effects to THC but isn't psychoactive. Early research suggests CBD may help AMD, but it is not endorsed by doctors. Age-related macular degeneration (AMD) is a leading cause of vision loss in the United States, with age and family being primary risk factors. While healthcare professionals do not currently recommend cannabis and CBD as a treatment option for macular degeneration or other eye health issues, ongoing research suggests it may one day be a possible treatment option for some people with this eye condition. Do CBD treatments help with macular degeneration? About macular degeneration treatments There are two kinds of age-related macular degeneration. Dry AMD is more common. Treatment for dry AMD includes taking specific nutritional supplements and using low-vision aids. Wet AMD is not as common, but it's more treatable. Treatments include anti-vascular endothelial growth factor (VEGF) eye injections and light therapy. Generally, cannabis use is linked to lowered eye pressure and is known to help lower inflammation throughout the body. Some people with AMD have reported anecdotal benefits from CBD use. This 2022 research in the United Kingdom (IK) does indicate that CBD may possibly lower the risk of this eye condition. However, there's not enough medical research overall to support CBD as a treatment for any type of AMD. In the UK study looking at people who'd used marijuana (including CBD) more than 100 times, they did see a lower risk for AMD. But the research also indicated people experienced higher rates of blood vessel loss, possibly leading to AMD development sooner for younger people. Research on this topic has also found that many forms of CBD can't be easily administered as treatments for eye conditions. For instance, CBD oils aren't the right consistency to be made into eye drops. Can you use CBD for other eye conditions? CBD is known to have an effect on eye pressure, which could be a meaningful benefit for acute or chronic eye conditions. For example, glaucoma is an eye condition that can lead to permanent vision loss, but it has a different cause than AMD. It's often caused by a buildup of eye pressure on your optic nerve (it sends visual information from your eyes to your brain). Lowering eye pressure could potentially lower the risk of glaucoma and help treat active cases. But research is conflicting and shows there may also be side effects of using CBD for glaucoma or other eye conditions, including mental health concerns, vision changes such as color blindness, retinal deterioration, and optic nerve damage. No enough research exists to support CBD as a treatment for eye pressure or as a way to lower the risk of either glaucoma or AMD. Results are conflicting. A 2018 study found that CBD (cannabidiol) eye drops increased eye pressure in rats. But the same study found that THC (tetrahydrocannabinol) eye drops reduced eye pressure by up to 30%. Treatment of AMD and glaucoma isn't the only possible eye-health-related use of CBD. Research is also being done into the use of CBD to help treat: diabetic retinopathy eye inflammation corneal inflammation eye pain Additional research is needed to determine if CBD or THC could be used in glaucoma or AMD treatment and prevention. Right now neither is approved for managing these conditions. Traditional AMD treatments Traditional, scientifically backed AMD treatment regimens depend on the type of AMD you have. They may include. Anti-VEGF injections: These injections are the most common treatment for wet AMD. They stop the growth of eye blood vessels and can prevent and possibly reverse vision loss. Light therapy: Known as photodynamic therapy, this treatment type may also be used to target and destroy blood vessels. Nutritional supplements: A combination of nutritional supplements known as the AREDS2 formula has been shown to help prevent further vision loss due to dry AMD. However, these supplements aren't proven to lower the chance of AMD onset overall. Low vision aids: These can help with any vision loss you experience due to either form of AMD or another condition. They are an essential tool in managing dry AMD. An eye doctor can help you determine the best options for you. Options may include wearing glasses, using a magnifying glass, large print materials, and an array of computer programs or mobile apps. How can you prevent macular degeneration? AMD is tied to multiple risk factors, many of which you can't control including age and genetics passed down through families. However, you can practice habits to support good eye health, which benefits your eyes lifelong. These may include: Getting regular eye exams. Don't smoke or quit smoking. Getting regular physical activity. Eating certain foods that may help your eye health, including low cholesterol foods.
Yahoo
4 hours ago
- Yahoo
Massive Review Finds No 'Safe' Level of Processed Meat Consumption
We know that processed meat isn't particularly good for us, having already been linked to dementia, diabetes, and cancer, but how much of it counts as a 'safe' level of consumption? According to new research, there's no such thing. US researchers reviewed over 70 previous studies (involving several million participants in total), analyzing the relationships between ultra-processed food and three health issues: type 2 diabetes, ischemic heart disease, and colorectal cancer. Associations for processed meat, sugar-sweetened beverages, and trans fatty acids were looked into, and it was the processed meat that came out with the worst results – even if the amount eaten is only small. "The monotonic increases in health risk with increased consumption of processed meat suggest that there is not a 'safe' amount of processed meat consumption with respect to diabetes or colorectal cancer risk," the team from the University of Washington in Seattle writes in their published paper. Related: It's important to put the research into context. The associations found are relatively weak, they don't prove direct cause and effect, and the analyzed studies relied on self-reported dietary habits (which may not be completely accurate). However, the study has several strengths too – it uses a Burden of Proof method, which is more conservative when assessing impacts on health. The results tend to be minimum values, which means they likely underestimate the true health risk. What's particularly notable here is that minimal increases in consumption still raised risk levels. "Habitual consumption of even small amounts of processed meat, sugary drinks, and trans fatty acids is linked to increased risk of developing type 2 diabetes, ischemic heart disease and colorectal cancer," University of Washington nutrition biologist Demewoz Haile told CNN. For example, the equivalent of one hot dog a day was associated with at least an 11 percent greater risk of type 2 diabetes, and at least a 7 percent greater risk of colorectal cancer, compared to eating no processed meat at all. For beverages, an extra can of sugar-sweetened pop a day was linked to a 8 greater risk of type 2 diabetes, and a 2 percent greater risk of ischemic heart disease, compared to not drinking anything sugary. For trans fatty acids, a small daily amount was associated with a 3 percent increase in risk of ischemic heart disease, compared with zero consumption. "This information provides critical data for public health specialists and policymakers responsible for dietary guidelines and potential initiatives that aim to reduce the consumption of these processed foods," write the researchers. While the study has limitations, its scale and conservative methodology make it worth taking note of. This is backed up by a commentary in the same journal, which does note the role of ultra-processed foods in improving food accessibility and shelf life, particularly in areas with limited access to fresh food. The message from the research team is that cutting out ultra-processed foods as much as possible is the best option for our health. The research has been published in Nature Medicine. Ozempic-Like Drugs Could Treat Chronic Migraines, Trial Finds Gut Bacteria Found to Soak Up Toxic Forever Chemicals Gene Therapy Can Restore Hearing in Adults, First-of-Its-Kind Trial Shows
